Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down – What’s Next?

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) gapped down before the market opened on Wednesday . The stock had previously closed at $33.02, but opened at $30.28. Rigel Pharmaceuticals shares last traded at $29.34, with a volume of 307,501 shares traded.

Key Headlines Impacting Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised its FY2026 EPS outlook for RIGL to $4.73 (from $3.14), signaling higher near-term profitability expectations that could support the share price if validated by results. HC Wainwright raises FY2026 estimate
• Neutral Sentiment: HC Wainwright published detailed quarterly EPS forecasts for 2026 (Q1 $0.95, Q2 $1.20, Q3 $1.27, Q4 $1.30) — useful for modeling quarterly cash flows and near-term earnings expectations but dependent on execution. HC Wainwright quarterly estimates
• Neutral Sentiment: Transcript of the recent earnings call is available for investors who want management commentary and detail behind guidance and revenue drivers. Review for color on contract revenue and pipeline timing. Earnings Call Transcript
• Negative Sentiment: Seeking Alpha reports RIGL shares slid after commentary that falling contract revenue will drive near-term revenue contraction — a direct negative for top-line growth and short-term cash flow expectations. Stock slides as contract revenue falls
• Negative Sentiment: TipRanks flagged newly disclosed FDA fast-track ambitions as carrying “significant FDA uncertainty,” highlighting regulatory risk that could delay approvals or change timelines for pipeline-related revenue. FDA fast-track uncertainty
• Negative Sentiment: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts (FY2027 to $3.85 from $3.92; FY2028 to $4.42 from $4.73), signaling more modest long-term growth expectations that could cap valuation upside. Later-year estimate reductions

Analysts Set New Price Targets

Several research firms have recently commented on RIGL. Wall Street Zen raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, Citigroup reaffirmed a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, January 14th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.67.

Rigel Pharmaceuticals Stock Down 0.4%

The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $545.23 million, a PE ratio of 1.56 and a beta of 1.10. The business has a fifty day moving average of $37.16 and a 200 day moving average of $37.32.

Insider Buying and Selling

In other Rigel Pharmaceuticals news, Director Walter H. Moos sold 4,000 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $36.36, for a total value of $145,440.00. Following the sale, the director owned 12,722 shares of the company’s stock, valued at $462,571.92. This trade represents a 23.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Rigel Pharmaceuticals

A number of large investors have recently modified their holdings of the company. AlphaQuest LLC increased its holdings in Rigel Pharmaceuticals by 234.8% in the third quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 775 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Rigel Pharmaceuticals by 400.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,020 shares during the last quarter. IFP Advisors Inc purchased a new stake in Rigel Pharmaceuticals in the 3rd quarter valued at $55,000. CWM LLC boosted its stake in Rigel Pharmaceuticals by 217.0% during the 4th quarter. CWM LLC now owns 1,791 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 1,226 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Rigel Pharmaceuticals during the 3rd quarter worth $62,000. 66.23% of the stock is owned by hedge funds and other institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).